Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial aldehyde dehydrogenase 2 (ALDH2) is a critical enzyme located in the mitochondrial matrix, primarily known for its role in the second stage of ethanol metabolism. It catalyzes the oxidation of acetaldehyde, a toxic and carcinogenic intermediate, into the less harmful acetate [1, 3, 10]. Beyond alcohol metabolism, ALDH2 serves as a vital detoxifying agent for reactive aldehydes generated during lipid peroxidation, such as 4-hydroxy-2-nonenal (4-HNE), which are implicated in oxidative stress and cellular damage [2, 6, 11]. A common genetic polymorphism, ALDH2*2 (rs671), results in a nearly inactive enzyme and is highly prevalent in East Asian populations, leading to alcohol flushing syndrome and increased susceptibility to esophageal cancer and cardiovascular diseases [5, 14, 16]. In clinical practice, ALDH2 is targeted by the inhibitor disulfiram to treat alcohol use disorder by causing an accumulation of acetaldehyde and subsequent unpleasant physiological reactions [13, 17, 19]. Emerging therapeutic strategies focus on ALDH2 activators, such as Alda-1, which aim to enhance the enzyme's activity to protect against ischemia-reperfusion injury in the heart and brain, as well as neurodegenerative conditions like Alzheimer's disease [4, 11, 15].
ALDH2 is targeted through two primary pharmacological approaches: inhibition and activation. Inhibitors like disulfiram block the enzyme's ability to metabolize acetaldehyde, leading to its toxic accumulation and inducing aversive symptoms (flushing, nausea) to deter alcohol consumption [13, 17]. Conversely, activators like Alda-1 enhance the enzyme's catalytic efficiency, particularly in individuals with the ALDH2*2 variant, to accelerate the detoxification of reactive aldehydes and mitigate oxidative damage in cardiovascular and neurodegenerative diseases [2, 4, 14]. Additionally, ALDH2 acts as a bioactivating enzyme for nitroglycerin, converting it into nitric oxide [7, 16].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aldehyde dehydrogenase, mitochondrial (ALDH2) (ALDH2).